Semaglutide vs. Tirzepatide: Published Research Comparison

Semaglutide and Tirzepatide are the two most-discussed GLP-family research analogs of the past decade. The 2021 SURPASS-2 trial (NEJM, PMID 34324827) compared them head-to-head in research populations with type-2 diabetes — making this comparison unusually evidence-rich. BioInfinity Lab's research analogs of both compounds (GLP-1-S and GLP-2-T respectively) ship same-day from New York.

Published February 8, 2026 · Reviewed by Dr. Marina Voss, PhD (Senior Research Reviewer)

Quick comparison

	Semaglutide (GLP-1-S)	Tirzepatide (GLP-2-T)
Mechanism	Single GLP-1 receptor agonist	Dual GLP-1 + GIP receptor agonist
First-described year	Around 2012 (research literature)	Around 2018 (research literature)
Major trial program	STEP, SUSTAIN, SELECT, PIONEER	SURPASS, SURMOUNT
Direct head-to-head trial	SURPASS-2 — NEJM 2021 (PMID 34324827)	Same trial
Research dose range (weekly subQ)	0.25–2.4 mg	2.5–15 mg
BioInfinity Lab SKU	/buy/glp1-s	/buy/glp2-t
BioInfinity Lab purity	≥99% HPLC + MS	≥99% HPLC + MS
Reported research half-life	~7 days (weekly dosing supported)	~5 days (weekly dosing supported)

Verdict: SURPASS-2 (NEJM 2021) is the foundational head-to-head publication. Researchers selecting between the two compounds for replication or extension studies should reference that paper. For new research investigating dual GLP-1 + GIP receptor pathways, GLP-2-T is the direct match; for single GLP-1 receptor research, GLP-1-S is the direct match.

Buy Semaglutide (GLP-1-S) →Buy Tirzepatide (GLP-2-T) →

The SURPASS-2 head-to-head publication

SURPASS-2 (Frias et al., NEJM 2021, PMID 34324827) compared Tirzepatide directly with Semaglutide in research subjects with type-2 diabetes over 40 weeks. The publication reports differentiated outcomes on multiple research endpoints — most notably A1C and body-weight endpoints — with Tirzepatide showing greater reported effects in the studied cohorts at the doses tested.

Researchers replicating or extending SURPASS-2 should refer directly to the NEJM publication for primary methodology, dosing schedule, and statistical analysis. The publication remains the most-cited head-to-head reference for these two compounds in 2026.

Mechanism: why the dual-receptor activity matters in research

Semaglutide is a single-receptor (GLP-1) agonist. Tirzepatide adds receptor activity at GIP, the second major incretin receptor. Research literature describes the dual-agonist mechanism as offering a differentiated receptor-engagement profile relative to single-agonist GLP-1 analogs.

For researchers extending the mechanism literature into new biological models, the receptor-binding profile is the central reason to select one compound over the other. Researchers studying single-pathway GLP-1 effects should select GLP-1-S; researchers investigating combined GLP-1 + GIP pathway effects should select GLP-2-T.

Reported dose ranges in published research

Semaglutide research protocols typically administer 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg weekly via subcutaneous injection, with a multi-week dose-titration phase. Tirzepatide research protocols typically administer 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly with a similar titration schedule.

Researchers replicating published trials should reference the specific paper for the exact dose-escalation protocol and follow IRB-approved guidelines for their own studies.

GLP-3-R: the next-generation triple-agonist in research

For researchers tracking the GLP-family research literature, the next major compound is Retatrutide — a triple GLP-1 + GIP + glucagon receptor agonist (NEJM 2023, PMID 37314979). BioInfinity Lab stocks the research analog at /buy/glp3-r. The 2023 Phase 2 publication is essential reading for researchers replicating or extending the triple-agonist literature beyond the two compounds compared here.

Frequently asked questions

Quick answers about the Semaglutide (GLP-1-S) vs Tirzepatide (GLP-2-T) comparison.

What's the main mechanism difference between Semaglutide and Tirzepatide?+

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 + GIP receptor agonist. The added GIP receptor activity is the central mechanistic distinction in the research literature.

Has there been a direct head-to-head trial?+

Yes — SURPASS-2 (NEJM 2021, PMID 34324827) compared the two compounds directly in research subjects with type-2 diabetes over 40 weeks. It remains the most-cited head-to-head reference.

What about Retatrutide / GLP-3-R?+

Retatrutide is a triple-receptor (GLP-1 + GIP + glucagon) agonist research analog. The 2023 Phase 2 NEJM publication (PMID 37314979) describes its research-pharmacology profile. BioInfinity Lab's research analog is at /buy/glp3-r.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.